SERBA-2

<p>SERBA-2, short for selective estrogen receptor beta agonist-2, is a <a href="/facts/Synthetic_compound/gqCNaN45">synthetic</a>, <a href="/facts/Nonsteroidal/7TUS4VXE">nonsteroidal</a> <a href="/facts/Estrogen/dPEewnDV">estrogen</a> which acts as a selective <a href="/facts/ER%25CE%25B2/lqHMPmUM">ERβ</a> <a href="/facts/Agonist/nz8U5NNp">agonist</a>. For the <a href="/facts/ER%25CE%25B1/PXU6tYY3">ERα</a> and ERβ, SERBA-2 has <a href="/facts/Affinity_(pharmacology)/44QLL4eU">affinities</a> (Ki) of 14.5 nM and 1.54 nM, <a href="/facts/Efficacy/PNlTeDtD">efficacies</a> of 85% and 100%, and <a href="/facts/EC50/x7oD7ITx">EC50</a> values of 85 nM and 3.61 nM, respectively, demonstrating 9-fold <a href="/facts/Binding_selectivity/RryTsdGv">binding selectivity</a> and 11-fold <a href="/facts/Functional_selectivity/jM5qoIPP">functional selectivity</a> for the ERβ over the ERα. An <a href="/facts/Enantiomer/wjPv5J3y">enantiomer</a> of SERBA-2, <a href="/facts/Erteberel/fmj1dztr">erteberel</a> (SERBA-1), is more <a href="/facts/Potency_(pharmacology)/D38FDyPh">potent</a> and selective in comparison and is under development for the treatment of <a href="/facts/Schizophrenia/FMP4lQ57">schizophrenia</a>.
</p>

SERBA-2 open-in-new

SERBA-2